Fusion Antibodies
FAB · AIM · Health Care · mcap £14m today
All announcements
-
05 Oct 26Launch of new customer-focused website
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the launch of its new customer-focused website.
RNS 9805360 ↗ -
15 Sep 26Final Results
The following amendment has been made to the announcement released on 14 September 2026 at 7am under RNS No.
RNS 9773630 ↗ -
14 Sep 26Final Results
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its final results for the year ended 31 March 2026.
RNS 9769010 ↗ -
09 Sep 26Grant of Canadian Patent for OptiMAL
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company's patent application no.
RNS 9763615 ↗ -
06 Aug 26Notice of acceptance of patent in Australia
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that IP Australia has issued a notice of acceptance in respect of the Company's...
RNS 9707342 ↗ -
22 Jun 26Notice of allowance of patent in Canada
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Canadian Intellectual Property Office has issued a notice of allowance in...
RNS 9628760 ↗ -
15 Jun 26Update on grant-funded DR5 project
Project to develop a DR5 humanised therapeutic antibody to combat treatment-resistant cancers
RNS 9617242 ↗ -
11 May 26Grant of patent in Japan
Grant strengthens antibody discovery platform and licensing opportunities
RNS 9561846 ↗ -
05 May 26Year-end trading statement
Positioning for growth through platform development and strategic partnerships
RNS 9550653 ↗ -
30 Mar 26Antibody IP transfer agreement
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has entered into an agreement to transfer the ownership of certain background...
RNS 9496984 ↗ -
27 Jan 26Issue of Director Shares
As disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the "Board" or the "Directors") accepted, a bonus...
RNS 9388207 ↗ -
27 Jan 26Placing and Subscription to raise approx £1.4m
Placing and Subscription to raise approximately £1.4 million
RNS 9388010 ↗ -
19 Dec 25Update on negotiations with NCI regarding OptiMAL
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute ("NCI")...
RNS 9307856 ↗ -
16 Dec 25
-
11 Dec 25Mammalian Display video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL® Human Antibody Discovery platform...
RNS 9289286 ↗ -
24 Nov 25Half-year Results
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30 September 2025 ("H1 FY2026").
RNS 9251785 ↗ -
13 Nov 25OptiMAL Library video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science...
RNS 9230310 ↗ -
03 Nov 25OptiMAL® R&D Update
Validation of OptiMAL® for the isolation of specific antibodies against proteins and peptides
RNS 9207403 ↗ -
16 Oct 25AGM statement and H1 trading update
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, Simon Douglas, Chairman, will...
RNS 9173988 ↗ -
08 Oct 25
Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.